GlassScriptPhysician profile
Evelyn Sdrulla
NPI 1649428152
$6,733.55
in general payments reported to CMS, 2019-2025
49 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,663 · 2022: $1,631 · 2023: $1,481 · 2024: $895 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,439.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,040.66 | 2021-2025 | |
| Amgen INC. | $588.33 | 2021-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $486.80 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Alkermes, INC. | $435.20 | 2021-2024 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $375.56 | 2021-2025 | Rexulti, Nuedexta |
| Lundbeck LLC | $328.68 | 2021-2025 | Rexulti, Brintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $297.15 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $244.98 | 2021-2023 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $224.30 | 2021-2025 | Farxiga |
| Biohaven Pharmaceuticals, INC. | $187.78 | 2021 | |
| Lilly USA, LLC | $184.77 | 2021-2024 | Mounjaro, Zepbound |
| Avanir Pharmaceuticals, INC. | $175.21 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $164.65 | 2022-2025 | Capvaxive, Gardasil 9, Gardasil |
| Eisai INC. | $160.89 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $155.82 | 2021-2024 | Ingrezza |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evelyn Sdrulla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.